Lilly and Daiichi-Sankyo announce heart attack study results

Lilly and Daiichi-Sankyo have announced results of a new study into heart attack patients.

The research saw non-fatal heart attack patients – who complained of chest pains within the first three months of hospitalisation – had a significantly higher risk of dying or having another attack in the following three to four years, compared to those who did not experience an attack in the same period.

Findings of the 15,000-patient study are to be presented at the International Society for Pharmacoeconomics and Outcomes Research’s annual meeting, held from November 8th to 11th.

Investigator and assistant professor of medicine at Duke University Medical centre and research institute in the US, David Kong, said: “This study illustrated that heart attack patients may still suffer severe, life-threatening events over the next several years, even if they appear well.”

“Surviving an initial heart attack does not mean that a patient is ‘out of the woods,'” he added.

Founded in 1876, Lilly has approximately 40,217 employees worldwide, of which 7,946 are within research.
The company additionally has clinical research conducted in more than 50 countries, with facilities located in eight, manufacturing plants in 13 and products in 143.